RAPT Therapeutics RAPT 深 沪
已收盘 02-06 16:00:00 美东时间
57.69
+0.010
+0.02%
华盛通- 最 高57.80
- 今 开57.70
- 成交量 359.15万股
- 最 低 57.64
- 昨 收 57.68
- 总市值 16.71亿
- 52周最高 57.86
- 市盈率 静 --
- 换手率 12.40%
- 52周最低 5.6656
- 委 比 74.00%
- 总股本 2896.06万
- 历史最高 409.68
- 量 比 0.66
- 振 幅 0.28%
- 历史最低 5.6656
- 每 手 1
- 风险率 13.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GSK shares uptick for seven consecutive sessions
GSK (GSK) shares clocked seven straight sessions of gains, as the stock rose 1.9% at $60.29 on Friday. The multinational healthcare giant gained 16.8% in the preceding six sessions. The stock has surg...
02-07 04:39
GSK wins EU nod to expand Nucala for COPD
GSK (GSK) on Friday announced that the European Commission has approved its Nucala asthma therapy for patients with chronic obstructive pulmonary disease (COPD), expanding its label into five disease ...
02-07 00:35
葛兰素史克预计2026年销售额增长放缓 新任首席执行官米尔斯准备改变路线
葛兰素史克GSK.L周三在新任首席执行官卢克-米尔斯（Luke Miels）发表的首份展望报告中表示，预计2026年的销售额增长将比上年 有所放缓，因为 该公司...
02-04 18:14
UPDATE 2-GSK expects softer 2026 sales growth as new CEO Miels prepares change in course
UPDATE 2-GSK expects softer 2026 sales growth as new CEO Miels prepares change in course GSK says vaccine and general medicines sales may decline in 2026 Company maintains long-term targets GSK shifting focus to pipeline expansion and commercial execution Q4 and 2025 sales beat analyst expectations
02-04 15:12
2026生物技术趋势前瞻 | 行研附报告
（来源：药研网） 图源： Stifel 2026 年，生物科技不再只靠“讲故事”，而是迈入以科研成果和数据驱动发展的新时代。 新型疗法加速成熟，肿瘤、代谢...
02-02 16:52
BREAKINGVIEWS-Big Pharma’s revenue hole requires a pricey fix
BREAKINGVIEWS-Big Pharma’s revenue hole requires a pricey fix The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, Jan 27 (Reuters Breakingviews) - The likes of Pfizer and Merck are facing looming patent cliffs which will expose $400 bln o
01-27 19:31
China approves GSK’s Trelegy Ellipta for adult asthma treatment
GSK (GSK) said on Friday that China’s National Medical Products Administration approved a new indication for Trelegy Ellipta to treat adults with asthma, expanding its approved use beyond chronic obst...
01-23 18:51
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
美股牛股 | Corvus制药飙升166%，皮炎新药1期临床试验结果积极；RAPT大涨逾60%
Corvus制药飙升166%，皮炎新药临床试验结果积极；RAPT大涨逾60%，获葛兰素史克以22亿美元溢价收购；黄金资源大涨24%，财报强劲叠加金银价齐创新高>>
01-21 18:51
